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SUMMARY 
 
Manganese has been used as a T1-weighted MRI contrast agent in a variety of 
applications. Because manganese ions (Mn2+) enter viable myocardial cells via voltage 
gated calcium channels, manganese-enhanced MRI (MEMRI) is sensitive to the viability 
and the inotropic state of the heart. In spite of the established importance of calcium 
regulation in the heart both prior to, and following, myocardial injury, monitoring 
strategies to assess calcium homeostasis in affected cardiac tissues are limited. This study 
implements a T1-mapping method to obtain quantitative information both dynamically 
and over a range of MnCl2 infusion doses. In order to optimize the current manganese 
infusion protocols, both dose dependent and temporal washout studies were performed. A 
non-linear relationship between infused MnCl2 solution dose and increase in left 
ventricular free wall relaxation rate (∆R1) was observed. Control mice also exhibited 
significant manganese clearance over time, with approximately 50% decrease of ∆R1 
occurring in just 2.5 hours. The complicated efflux time dependence possibly suggests 
multiple efflux mechanisms. Using the measured relationship between infused MnCl2 and 
∆R1, absolute Mn concentration ICP-MS data analysis provided a means to estimate the 
absolute heart Mn concentration in vivo. We have shown that this technique has the 
sensitivity to observe or monitor potential Ca2+ handling alterations in vivo due to the 
physiological remodeling following myocardial infarction. Left ventricular free wall ∆R1 
values were significantly lower (P = 0.005) in the adjacent zone, surrounding the injured 
myocardial tissue, than healthy left ventricular free wall tissue. This inferred reduction in 
Mn concentration can be used to estimate potentially salvageable myocardium in vivo for 
future therapeutic treatment or evaluation of disease progression. 
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CHAPTER 1 
INTRODUCTION 
 
 
 
Intracellular calcium is a central regulator of cardiac contractility and viability (1). 
Calcium (Ca2+) entry through L-type Ca2+ channels into cardiac myocytes is known to be 
the initiating event of the excitation-contraction coupling process (2,3). Calcium entering 
cells during each action potential must be pumped out of the cell to maintain composition 
of the cytosol at a steady state. There are two known mechanisms to remove Ca2+ from 
cardiac cells (4), either via the sodium-calcium exchanger (NCX), or via the plasma 
membrane Ca2+-ATPase (PMCA) (5). 
Alterations in myocyte Ca2+ handling appear to be centrally involved in the 
dysfunctional characteristics of the failing heart (6). It has been demonstrated that the 
principle cause of diminished cardiac performance in the failing heart is due to abnormal 
intracellular Ca2+ handling impairing cardiomyocyte contractility (7,8). During ischemia 
the sodium-hydrogen exchange mechanism can lead to intracellular sodium overload. 
This in turn leads to reduced calcium efflux and/or increased calcium influx via the 
sodium-calcium exchanger mechanism, resulting in intracellular calcium overload (9). 
Cell death can result from one of several mechanisms following elevations in intracellular 
calcium concentration. Examples of these mechanisms include protease activation, 
membrane rupture, cell contracture, and gap junction dysfunction (9,10). 
Following myocardial infarction there is progressive myocardial remodeling 
characterized by left ventricular dilation, contractile dysfunction and myocyte 
hypertrophy. There are also altered expressions of contractile, calcium-handling, and 
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extracellular matrix proteins (11). Similarly, myocardial ischemia appears to have 
significant negative effects both on acute and chronic cardiac remodeling and on damage 
to other organs, including the vascular endothelium (12,13), kidney (14), skeletal muscle 
(15,16), and brain (17).  
In spite of this established importance of calcium regulation in the heart both prior 
to, and following, myocardial injury, monitoring strategies to assess calcium homeostasis 
in affected cardiac tissue are limited. In addition, there are currently no in vivo techniques 
available to study calcium fluxes dynamically over the myocardium. This present study 
proposes using a T1-mapping manganese-enhanced MRI technique, with the goal of 
studying changes in calcium uptake due to myocardial injury in both the myocardial 
infarction injury site and also in the adjacent zone, surrounding the infarcted region. Such 
a technique could allow for identification of potentially salvageable myocardium and for 
differentiation between ischemic, hibernating and stunned myocardium. 
 
1.1 Manganese (Mn2+) as an MRI contrast agent 
 
One potential technique for assessing intracellular calcium is to use a surrogate 
marker with a comparable ionic radius, such as manganese (Mn2+). Mn2+ is an excellent 
candidate due to its similar chemical properties to calcium; additionally, its shortening of 
the T1 relaxation time allows it to serve as an MR contrast agent (18,19). As a result of 
these chemical properties, Mn2+ has the potential to enter viable myocardium via voltage 
gated calcium channels (20-22), accumulating in the myocytes in an additive fashion 
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(23,24). These factors combined make Mn2+ a useful molecular agent for the study of 
calcium flux. 
In its ionic form, Mn2+, along with other elements from the transition metals and 
the lanthanide series, exacts a dramatic effect on relaxation properties of water. There are 
multiple components that compromise the MRI signal following interaction of these ions 
with excited 1H nuclei. The longitudinal relaxation time, T1, of the 1H nuclei can be 
shortened following interaction of the ionic dipoles with the nuclear 1H dipole. The 
magnitude of this interaction depends on the approach distance between 1H and the ion, 
which may be large and lead to a small interaction if the ion is part of a larger molecule, 
such as deoxyhaemoglobin (deoxyHb). The duration of the coupling between the 1H and 
ionic dipoles, the correlation time, also affects the magnitude of the dipole-dipole 
interaction. If the ion is not chelated, as is the case with MnCl2 used in this study, it will 
have a wide range of rotational velocities compared to the excitation frequency of 1H, so 
the dipole-dipole interaction will be weaker.  
For suitable rotational rates, the correlation time will depend on the electron spin 
relaxation time of the agent (25), where slower electronic relaxation results in greater 
coupling of the dipoles. Electron spin relaxation times for ionic Mn2+ and Gd3+ are 
relatively slow, in the range of 10-8 – 10-10 seconds (26,27).  
Mn2+, with a relatively long spin relaxation time, will tend to stimulate spin-flip 
transitions effectively and is useful for enhancing contrast positively on T1-weighted 
images. At higher concentrations, Mn2+ is also useful for increasing T2 relaxation (28). 
The use of Mn2+ to produce shortening of the spin-lattice relaxation time, T1, was 
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proposed soon after the conception of using NMR for radiological imaging. In 1973 
Lauterbur (29) used Mn2+ to shorten T1 in a pure water sample. 
 
1.2 Manganese-enhanced MRI (MEMRI) 
 
Alterations in myocyte Ca2+ regulation may be critical for both the mechanical 
dysfunction and the arrhthmogenesis associated with congestive heart failure (30,31). 
Recent advances have improved the feasibility of studying ischemic heart disease with 
MRI (32). MR contrast agents can be applied in a variety of ways to improve MRI 
sensitivity for detecting and assessing injured myocardium, and have the potential to be 
used to detect regional differences in cellular viability within the injured heart. Contrast 
enhanced perfusion MRI has been used to explore disturbances in both large 
(angiography) (33) and small (myocardial perfusion) (34) coronary arteries. It is known 
that the size of the abnormal signal area on Gd-enhanced T1-weighted MRI correlates 
well with infarct area (35). However, the size of the nonperfused area on first-pass 
perfusion images is often smaller than the final infarct area. Therefore, there is a need to 
obtain other measures of cell viability. 
The application of Mn2+ contrast enhancement to cardiac MRI, either in the form 
of paramagnetic free manganese (e.g. MnCl2), or in a chelated form (e.g. manganese 
dipyridoxyl diphosphate, MnDPDP), allows for the potential monitoring of calcium 
dynamics, of particular importance in the infarcted heart. Chelation of the paramagnetic 
ions decrease their rotational velocity and increase the correlation time, both beneficial in 
increasing T1 relaxation. However, chelates also alter the approach distance, decreasing 
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the contrast agent’s effect on T1. In order to achieve the same relaxation effects as free 
ions, larger doses of the chelate need to be administered. A valuable added benefit of 
using a chelate is that, for less chemically-reactive but toxic metals such as Gd3+ and 
Mn2+, the chelated complex is excreted from the body within a timescale that greatly 
decreases the toxic side effects. However, the slow release of Mn2+ from chelates, as 
compared to free ions, make the quantitative study of Mn2+ influx rates more 
complicated.  
Manganese-enhanced MRI (MEMRI) has been employed in a wide range of 
biological studies including the study of neuronal activity (36-38), function (39,40), 
plasticity (41), and the neural circuitry involved in more complex cognitive and 
emotional processes (42). Recently it has also been applied to studying in vivo axonal 
transport rates in Alzheimer’s disease models (43,44). MEMRI has been used in other 
areas to label lymphocytes and B-cells (45) and to detect beta-cell activation (46).  
Additionally, MEMRI has been used to detect cell viability in the ischemic 
heart (47-49). A study to assess whether normal myocardial tissue can be differentiated 
from infarcted tissue using contrast agent Mn-DPDP has been conducted in rats (50). 
Infusion of various doses of the Mn2+ chelate demonstrated that Mn2+ was retained in the 
viable myocardium, but was shown to have rapid clearance from the infarcted region. 
This demonstrated the ability of the contrast agent to differentiate infarcted tissue from 
viable tissue. Similarly, in its free paramagnetic form MnCl2 has been shown to 
demarcate infarcted zones in mice (51) and dogs (52). 
More recently work has been completed studying the relaxation enhancing 
properties of MnDPDP in the human myocardium (53). In this particular study by Skjold 
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et al., R1 measurements were calculated for the myocardium of fifteen healthy patients 
using an inversion recovery (IR) turbo fast low-angle shot (FLASH) sequence, both 
before and at various time points post i.v. MnDPDP injection. Left ventricular wall R1 
values increased on average 37% one hour following a MnDPDP dose of 5 μmol/kg, the 
clinical liver dose. This elevation remained for approximately two hours, before a gradual 
decline lasting over 24 hours. Varying the dose of MnDPDP injections did not cause the 
R1 values to increase linearly. 
Following this work, Skjold et al. (47) performed a study on patients with recent 
myocardial infarction. The aim was to see if regions of the left ventricular wall would 
show signs of reduced R1 compared to healthy myocardial tissue after a low dose of 
MnDPDP. The results showed that reduced wall thickening at the infarction site was 
associated with reduced contrast enhancement. In contrast, the remote regions showed 
larger increases in R1. This is most likely due to the selective and slow Mn accumulation 
in viable myocytes. Conclusions drawn from this work suggest that the demarcation of 
infarcted myocardial regions is possible with manganese-based MRI contrast. The 
combination of low doses of MnDPDP with R1 mapping techniques can reliably identify 
infarcted regions. One potential advantage of using Mn2+ over Gd3+ in contrast enhanced 
studies is that Mn2+ could allow for the study of calcium fluxes. Also, Mn2+ could have 
the sensitivity to detect changes in calcium fluxes, not only in the infarcted region but 
also in the adjacent zone surround the MI site. 
Mn2+ infusion in mice has been shown to lead to significant signal enhancement 
in T1-weighted cardiac MRI (23). It has also been demonstrated that MEMRI is sensitive 
to changes in inotropy (23), consistent with the model that Mn2+-induced enhancement of 
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cardiac signal can be used to detect changes in the rate of calcium influx into the heart. 
While an essential element for the normal physiological functioning in all animal species, 
with an estimated safe and adequate daily dietary intake (ESADDI) of 2 – 5 mg Mn/day 
in adults (54), at high concentrations Mn2+ is know to be cardiotoxic (55). Previously, a 
dose-dependent study (23) determined a range of Mn2+ infusion doses that result in large 
signal enhancement without affecting the left ventricular ejection fraction or heart rate.  
 
1.3 T1-Mapping Cardiac MEMRI in the study of calcium homeostasis alteration 
 
In order to determine the relationship between the MnCl2 infusion dose and the 
calculated absolute tissue relaxation times due to Mn2+ uptake in murine cardiac 
myocytes, a quantitative imaging technique is required.  
T1-mapping protocols provide such a quantitative technique, allowing for 
estimations of absolute T1 values. Experiments aimed to measure tissue T1 and T2 
relaxation times were conducted as early as 1971, where discriminations between normal 
tissue and malignant tumor specimens were discerned from their relaxation times (56). In 
the late 1970’s Mansfield et al. extended these techniques to imaging biological 
structures (57,58). 
Quantitative MEMRI T1-mapping has been applied to numerous fields, for 
example MEMRI T1-mapping has been used to improve neuronal tract tracing techniques 
(59). In neuronal tract tracing Mn2+ causes a wide range of T1 changes, varying from 
short T1 values at the injection site, to longer values in more distant regions. In this 
particular study Chuang et al. (59) used a Look-Locker T1-mapping protocol that 
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displayed the sensitivity to detect the full range of T1 values with full brain coverage in a 
reasonable time. It was concluded that the use of quantitative techniques in MEMRI 
should allow for the study of more extensive pathways, and should allow for 
administration of lower Mn2+ doses. 
T1-mapping has also been applied to the study of the common neuropsychiatric 
condition hepatic encephalopathy (HE) (60). Within clinically relevant acquisition times 
significant correlations between the change in T1, due to deposition of manganese, and 
HE severity have been shown in the globus pallidus, the caudate nucleus, and the 
posterior limb of the internal capsule. 
In many MEMRI experiments there are a large range of T1 values within the field 
of view (FOV), such as those experienced in the mouse brain following systemic 
administration of MnCl2 (61). T1 weighted images need to be optimized in order to detect 
a specific range of T1 values. However, it is not typically possible to detect the complete 
range of T1 values using just one protocol, and acquisition of multiple images is required. 
Similarly, small changes in T1 values could provide important information that T1 
weighted imaging techniques do not have the sensitivity to detect. Utilizing a quantitative 
technique provides a greater sensitivity to a wide range of T1 changes, and also allows for 
reduced doses of Mn2+ to be administered. By reducing the dose, potential cardiotoxic 
and neurotoxic effects caused by high levels of Mn2+ can be minimized. Spin-echo 
inversion recovery (IR) techniques can be used to estimate T1 values, but the long echo 
times (TE) required in this sequence cannot be used with the relatively fast heart rate of 
the mouse. 
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The goal of using a quantitative technique within this study is to estimate the 
delivery of Mn2+ to viable myocardium in vivo, with applications to assess regional Mn2+ 
handling alterations in a myocardial infarction model. In 1970, a commonly used method 
to calculate T1 values was introduced by Look and Locker (62,63), whereby T1 relaxation 
times can be estimated using a periodic train of excitation pulses, sampling multiple time 
points during signal recovery. This method can significantly reduce scanning time 
without sacrificing accuracy, and has been shown to have almost the same efficiency as 
the spin-echo IR method in terms of the SNR per unit time (59,64). Following the 
description of Look-Locker (LL) T1-mapping presented by Chuang et al.(59), multiple 
time points are sampled during the relaxation following an inversion pulse separated by 
the interexcitation interval τ. This sampling is achieved using RF×N  pulses of the same 
flip angle (FA), α. Both Look and Locker (63) and Brix et. al (65) derive an expression 
for the signal evolution in the above LL T1-mapping protocol. The partially relaxed 
longitudinal magnetization, )(nM , before each excitation pulse, can be described by an 
exponential recovery with time constant *1T . 
[ ] 1,,1,0,)0()()()( *1/ −⋅⋅⋅=−∞−∞= − NneMMMnM Tnτ ……..(1) 
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The T1 value for each pixel can be calculated by obtaining *1T  from a three-
parameter fit to equation 1, and substituting this into equation 2. However, this assumes 
that the exact FA is known for each pixel, which is a poor assumption. Due to 
inhomogineities in the B1 field caused by imperfect excitation pulses and the RF coil 
profile, the FA differs from the intended value. This can be overcome by taking the 
relationship between )(∞M  and )0(M , with T1 being simplified to )(/)0(*1 ∞MMT  
when *1T<<τ , as shown by Steinhoff et. al (66). Chuang et al. (59) demonstrate how 
)0(/)( MM ∞ , *1T , and therefore T1, can be obtained independent of knowing the precise 
FA, and without the requirement that τ  and Td, the delay time between the inversion and 
the first excitation pulse of a slice, are short. This is achieved under the assumption that 
the longitudinal magnetization before each inversion pulse has reached steady state. 
Such a Look Locker T1-mapping MRI pulse sequence is applied in this study, 
with a total imaging time per T1 map of approximately 43 minutes. The study aims to 
characterize the relationship between the infused MnCl2 dose and the absolute tissue 
relaxation times, which could be used to optimize current manganese infusion protocols 
by minimizing the potential toxic effects of Mn2+ while still achieving adequate signal 
enhancement. By fitting this dose dependent data to ex vivo absolute Mn concentration 
values it could be possible to produce Mn concentration maps and to quantify the 
manganese content in vivo. 
In order to obtain reliable relaxation rate data and accurate dose dependent 
calibrations the T1 maps must be acquired at the appropriate time. The T1-map sequence 
should not be initiated until after assumed blood pool washout, and acquisitions should be 
minimized during any periods of rapid temporal signal washout that may occur. Blood 
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pool washout has been estimated to occur over the order of approximately 15 minutes in 
a canine model (52). In this present study a temporal signal washout curve was produced 
from T1 maps acquired at multiple time points post-infusion. The form of this curve could 
also provide information about the manganese efflux mechanisms. 
One of the primary goals of this study is to characterize the efficacy of MEMRI 
T1-mapping in assessing the dynamic features of calcium response due to myocardial 
injury in a small murine model. To achieve this Mn concentration map data was acquired 
for a myocardial infarction model allowing for estimates of the absolute Mn 
concentration both within the injury site and in the adjacent zone. The sensitivity of this 
technique could be used for potential pre-clinical and translational models to allow for 
treatment monitoring and for identifying potentially salvageable myocardium. 
12 
CHAPTER 2 
MATERIALS AND METHODS 
 
 
 
2.1 Animal Preparation 
 
Manganese-enhanced MRI experiments were performed in adult male C57Bl/6 
mice (5-13 weeks old, mean ± SD weight 22.6±2.2 g) following the guidelines of the 
Animal Care and Use Committee and the Animal Health and Care Section of the Institute 
(Medical College of Georgia, Augusta, GA, USA). The animals were initially 
anesthetized with a mixture of medical air, oxygen (1:1), and 2.5% isoflurane, positioned 
prone upon the animal cradle and maintained at 1.25±0.32% isoflurane throughout the 
MRI session. This protocol was established to maintain a relatively constant level of 
anesthesia and heart rate (460±30 bpm) during the MRI experiment. A custom made 
water bed was placed in the mouse cradle to maintain a constant temperature of 37.8 °C 
throughout imaging. 
A tail vein line for manganese infusion was introduced after anesthesia. A 60 mM 
MnCl2 solution was produced by dissolving MnCl2 crystals in saline. For the dose 
dependent study, MnCl2 was infused into control mice at doses ranging from 25 to 297 
nmoles/g total body weight (BW). This dose range had previously been shown not to 
cause cardiac depressive effects (23). For the temporal washout study, a single dose of 
282.57±5.96 nmoles/g BW was infused into the control mice. All infusions were 
completed at a constant rate of 0.6 ml/hr with the aid of a syringe pump (KD Scientific 
Inc., Holliston, MA, USA). 
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2.2 Myocardial Infarction Model 
 
For the myocardial infarction study the mice were divided into three experimental 
groups: control (n = 6, 22.57±3.24 g), sham-operated (n = 21, 23.06±2.48 g) and 
myocardial infarction (MI) (n = 6, 23.24±1.02 g). The control group underwent no 
surgical procedures. The sham-operated and MI groups were anesthetized with an 
intraperitoneal ketamine/xylazine cocktail and placed in a supine position. A midline 
cervical incision was made to intubate the trachea. The intubated mice were connected to 
a rodent ventilator (CWE Inc., Ardmore, PA, USA) and were ventilated at a respiratory 
rate of 90 breaths per minute. The chest was opened by middle thoracotomy at upper 
sternum, between the fourth and fifth ribs. The sham-operated mice underwent open chest 
procedures without ligation of the left anterior descending (LAD) coronary artery. In the 
myocardial infarction studies, myocardial infarcts were produced by permanently ligating 
the LAD. The LAD was ligated at a position ~1 mm below the left auricle with an 8-0 
polypropylene monofilament suture (Ethicon Inc., Somerville, NJ, USA). The mice were 
allowed to recover in a recovery chamber at 38 ºC, and then were rested prior to imaging 
sessions. 
Imaging was performed 13±4 days and 12±6 days post-surgery for the MI and 
sham-operated groups, respectively. The date range for imaging the MI mice was chosen 
from survival data for mice that have undergone MI surgery, according to the previous 
experiences within the lab. At approximately 10-13 days post-surgery the survival curve 
for MI mice has been observed to reach a plateau, suggesting an ideal time to image. 
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From prior experience it was also determined that at shorter times post-infarction 
the heart is going through a remodeling process involving multiple inflammatory 
processes. The inflammatory cells (i.e. macrophages) are also known to uptake Mn2+ 
(45). Imaging at this early time point post-infarction has therefore been reserved for 
future studies. Conversely, at long times of approximately 30 days post-infarction the 
mice experience heart failure. 
The aim of this study is to characterize the efficacy of MEMRI T1-mapping for 
assessing alterations in calcium homeostasis. To accomplish this aim, cardiac images 
were acquired at two time points, pre- and post- myocardial infarction, in a small murine 
model. The post-MI time point was chosen to emphasize calcium alteration after MI, 
while avoiding the pathological complexity of heart failure at later times. 
For MnCl2 administration in the myocardial infarction study, a tail-vein infusion 
line was placed and all three groups of mice were infused with 282.50±4.00 nmoles/g 
BW MnCl2 at a constant rate of 0.6 ml/hr. 
 
2.3 MRI 
 
Images were acquired on a 7.0-T 20-cm horizontal bore BioSpec MRI 
spectrometer (Bruker Instruments, Billerica, MA, USA) equipped with a micro imaging 
gradient insert (950 mT/m). Animal setup procedures followed those previously 
described (23). A standard Bruker volume coil (35 mm inner diameter, Bruker 
Instruments, Billerica, MA, USA) was used to transmit and receive at 1H frequency (300 
MHz). ECG and respiratory signals were monitored by a physiological monitoring 
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system (SA Instruments, INC., Stony Brook, NY) with the ECG signal used to gate the 
MRI Gradient Echo Flow Compensation (GEFC) pulse sequence (67). All images were 
gated to be acquired directly after the ECG R-wave at end-diastole. For the MI group 
accurate gating was achieved due to regular ECG signals in our imaging timeframe post-
infarction. The ECG signal is expected to become more problematic at longer times as 
the MI progresses. Breathing artifacts were minimized by securing the mouse in a custom 
made mouse holder. 
Short axis images were acquired for the control and sham-operated mice midway 
through the left ventricle and perpendicular to the long axis of the heart. In the 
myocardial infarction group the short axis was again defined perpendicular to the long 
axis of the heart, but located at the area with the greatest LV wall-thinning due to the 
injury. This was typically within 1 mm of the center of the ventricle. The imaging 
parameters were as follows: matrix = 128 x 128; TE = 3.5 ms; TR = 35 ms; slice 
thickness = 1.0 mm; FOV = 3.0 x 3.0 cm; flip angle = 60° and six averages. The 
repetition time, TR, for the gradient echo sequence was purposely set at a time shorter 
than the RR period (130±2 ms). The true repetition time for the imaging sequence was 
therefore the RR period. 
Both pre-MnCl2 and post-MnCl2 T1 maps were acquired with a ECG-gated, flow-
compensated Look-Locker MRI pulse sequence (matrix = 128 x 128; TE/TR = 2.5 ms/10 
sec; slice thickness = 1.0 mm; FOV = 3.0 x 3.0 cm; NA = 2; inversion time = 9 ms; 
average echo interval = 130 ms; number of echo images = 50; flip angle = 10°) as 
previously described (59). The echo interval was set as the approximate mean RR period 
observed prior to the execution of each T1 map sequence. The initial echo per repetition 
16 
was gated, with the subsequent echo pulses separated by the constant echo interval. The 
T1 value estimations are therefore not affected by any RR period fluctuations that may 
occur during TR. Post-infusion T1 maps were acquired approximately 5 mins after 
completion of the infusion to allow for assumed Mn2+ blood pool clearance. The total 
imaging time per T1 map was approximately 43 minutes. T1 maps were acquired both 
pre-MnCl2 infusion and post-MnCl2 infusion to allow the calculations of change in T1 
relaxation rate, ∆R1, due to the infusion. 
 
2.4 Analytical Procedures 
 
Control mice were sacrificed immediately after imaging. Absolute manganese 
content for heart and blood samples were measured by inductively coupled plasma-mass 
spectrometry (ICP-MS) analysis (CANTEST Ltd., North Vancouver, BC, Canada). 
 
2.5 Data Analysis 
 
T1-mapping 
The T1 value of each pixel was calculated using a custom-written C++ program 
(59). The signal recovery of each pixel was fitted from the 50 echo images by the three-
parameter Levenburg-Marquardt non-linear curve-fitting algorithm. Region-of-interest 
(ROI) analysis was performed on the 2D T1 maps using AMIDE (68) to calculate the 
average regional T1 value. In the case of the control and sham-operated mice, ROI tools 
were used to select a region of interest within the left ventricular free wall (LV Wall). To 
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quantitatively assess the dynamic features of the calcium response due to the myocardial 
injury additional regions of interest were defined for the MI group. The adjacent zone 
ROIs were defined in the regions of the LV Wall immediately surrounding the injury site, 
starting at the outer boundary of the left ventricular thinning and extending approximately 
1.5 mm into the viable tissue. An additional ROI, the myocardial infarction ROI (MI), 
was created within the injury site of the left ventricular free wall. In vivo ∆R1 values were 
calculated as (post-MnCl2 infusion R1) – (pre-MnCl2 infusion R1), where the relaxation 
rate, R1, is defined as 1/T1. ∆R1 values are quoted as a mean ± standard deviation, in units 
of (1/sec). 
Knowing the MnCl2 infusion dose, the ex vivo absolute manganese values were 
correlated to the in vivo ∆R1 values, allowing for an estimate of the absolute Mn content 
in the heart. From this information in vivo absolute Mn concentration maps were 
produced based on a relationship between R1 values in the LV Wall and interventricular 
septum post-infusion, and the absolute Mn elemental analysis results. 
 
 
Statistics 
The differences in manganese induced relaxivity changes between the three 
animal groups in the myocardial infarction study were assessed using ANOVA with a 
Bonferroni correction test between sub-groups. The threshold for significance was set at 
α = 0.05. Differences between individual groups were assessed using a two-tailed t-test, 
with the significance threshold set at p < 0.05. 
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CHAPTER 3 
RESULTS 
 
 
 
Sample ECG gated short-axis cardiac MRI images for a control mouse are shown 
in Figure 1. Figures 1a and b show the T1-weighted signal intensity enhancements pre- 
and post-MnCl2 infusion, respectively. Figures 1c and d show the corresponding T1 maps 
pre- and post-MnCl2 infusion, respectively. At this MnCl2 dose of 280 nmoles/g BW 
there is significant signal intensity enhancement in the myocardium following MnCl2 
infusion. For the control mice, a region of interest (ROI) was created for the left 
ventricular free wall (LVWall), Figure 1b. T1 values were obtained from both pre-MnCl2 
infusion T1 map ROIs and post-MnCl2 infusion T1 map ROIs and ∆R1 was calculated as 
the difference between these two T1 values (∆R1 = ∆(1/T1)).  
 
3.1 Concentration Dependent Study 
 
In order to produce in vivo Mn concentration maps, two pieces of information are 
required. One is the dependence of manganese infusion dose on LV Wall relaxivity, and 
the other is the absolute tissue Mn concentration following manganese infusion. The 
effect of altering the infusion dose on LV Wall ∆R1 is shown Figure 2, with the data 
summarized in Table 1. The post-MnCl2 infusion T1 map sequence was initiated 
approximately 5 minutes post-infusion. The summarized T1 map data points are shown as 
triangles in Figure 2, with the sample size and uncertainty (±1 SD) shown. The first two 
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Figure 1 - Example short-axis heart images for a control mouse. (a) T1-weighted pre-
MnCl2 infusion image; (b)T1-weighted post-MnCl2 infusion image; (c) pre-MnCl2 
infusion T1 map; (d) post-MnCl2 infusion T1 map. (b) shows the locations of the 
interventricular septum (S), left ventricular free wall (LVWall), liver (L) and chest wall 
(CW) 
 
 
 
columns in Table 1 display the grouped MnCl2 infusion doses and corresponding LV 
Wall ∆R1. The sample sizes are displayed in parentheses. ∆R1 values ranged from 0.16 
/sec for the lowest dose regime, up to an average of 4.61 /sec for doses above 197 
nmoles/g BW  
Also shown in Figure 2 and Table 1 are the elemental analysis results for the heart 
tissue and blood sample absolute manganese concentrations. Absolute manganese 
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Figure 2 - Effect of altering the dose of infused MnCl2 on left ventricular free wall 
relaxivity (triangles). The x-axis shows the total dose of infused MnCl2 normalized to 
mouse BW. The y-axis shows the relaxivity change, ∆R1, pre- vs. post-MnCl2 infusion. 
As a function of dose, two linear dose uptake regions were noted, along with a plateau 
region above 197 nmoles/g BW. The least square fits are shown with total MnCl2 
infusion dose, X, in nmoles/g BW. Comparison of this data to the total heart manganese 
concentration (μg/g dry) as determined by ICP-MS (squares) is also shown. This plot can 
be used to estimate the Mn concentration in vivo 
 
 
 
concentration values were quantified using ICP-MS, and are shown in columns 3-5 of 
Table 1. 
Three regions can be fit to Figure 2. At MnCl2 infusion doses, X (nmoles/g BW), 
below 197 nmoles/g BW two linear uptake regimes can potentially be fit to the data, 
intercepting at 61 nmoles/g BW. Above 197 nmoles/g BW, the relaxivity enhancement 
reaches a plateau. Within this physiological steady state any further increase in MnCl2 
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Table 1 - Dose dependent T1 map ∆R1 values for the LV Wall are shown in columns 1 and 2. ICP-MS absolute blood and heart 
manganese values from mouse samples are displayed in columns 3-5. LV Wall ROI absolute Mn concentrations from the calculated 
concentration maps are given in the final column. 
 
MnCl2 Infusion Dose 
(nmoles/g BW) 
LV Wall ∆R1 
(1/sec) 
MnCl2 Infusion 
Dose for Elemental 
Analysis (nmoles/g 
BW) 
Heart Absolute 
Mn 
Concentration 
(μg/g dry weight) 
Blood Absolute 
Mn 
Concentration 
(μg/ml) 
Concentration Map 
LV Wall ROI Data 
(nmoles/g) 
38.34±11.98 (n=3) 0.16±0.17 37.55±16.82 (n=2) 8.15±6.04 0.22±0.04 6.48±7.78 
65.46±8.16 (n=2) 0.33±0.29 - - - 12.22±8.87 
86.21±4.37 (n=5) 1.23±0.84 83.85 23.78 0.41 36.05±23.91 
108.33±8.09 (n=3) 1.96±0.34 108.87±11.36 (n=2) 53.87±3.31 0.41±0.03 63.16±10.65 
132.98±5.92 (n=4) 2.23±0.87 130.38 52.32 0.53 80.04±35.68 
156.17±7.01 (n=2) 3.67±0.15 156.17±7.01 (n=2) 72.72±1.03 0.55±0.09 114.52±13.04 
189.89±13.59 (n=2) 4.26±1.24 199.50 132.74 0.61 139.74±77.11 
230.40±15.10 (n=3) 4.83±2.02 243.17 151.35 0.69 166.41±77.11 
283.13±9.73 (n=6) 4.49±1.63 - -  221.97±131.13 
 
Values are expressed as mean ± SD, with sample size in parentheses 
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dose does not result in any apparent increase of ∆R1. The plateau occurs at ∆R1 = 
4.61±1.64 /sec. The best fit for the two phases below 197 nmoles/g BW have the form 
0.107-0.007X  R low1, =Δ  (r2 = 0.999) and 1.613-0.032X  R high1, =Δ  (r2 = 0.971) for the 
doses below and above 61 nmoles/g BW, respectively. This biphasic fit is consistent with 
findings from data from our lab taken in a rat model. The lower curve is fit under the 
assumption that 0  R1 =Δ  below 16.3 nmoles/g BW. This is deduced visually from Figure 
2 and is consistent with the fact that there is initially a non-zero volume of saline infused 
prior to Mn2+ entering the mice, inherent in the infusion line setup. For the average 
mouse weight of 22.6±2.2 g, the average dose of saline present in the infusion line is 
16.3±0.7 nmoles/g. The correlation between the infused MnCl2 dose, X (nmoles/g BW), 
and absolute heart Mn concentration, Y (μg/g dry weight), can be fit linearly with 
25.9-0.70X  Y =  (r2 = 0.94, Figure 3a). Similarly, the effect of altering the dose of 
infused MnCl2 on absolute blood sample manganese concentration, Z (μg/ml), yields a 
linear relationship of 0.160.002X  Z +=  (r2 = 0.93, Figure 3b). 
One of the primary goals for this study is to quantitatively estimate the absolute 
manganese map for the heart, in vivo. The data presented in Figure 2 shows the 
relationship between ∆R1 and the absolute heart manganese concentration, where the 
elemental analysis data points (square data point) are overlaid onto the dose dependent 
plot (triangular data points). Using the data obtained from this dose dependent study a 
myocardial relaxivity of 5.17 mM-1s-1 was estimated, based on the measured R1 values in 
the myocardium and from the elemental analysis measurements. Using this relaxivity, in 
vivo absolute Mn concentration maps (nmoles/g) were produced. The LV Wall ROI data 
for these maps are shown in the final column of Table 1. 
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Figure 3 - Effect of MnCl2 infusion dose on the total manganese concentration 
determined by ICP-MS for (a) the heart and (b) blood. The x-axis shows the total dose of 
MnCl2 infused. The y-axis shows the absolute manganese concentration in μg/g dry 
weight for the heart and μg/ml for the blood. Both plots show the linear least square best 
fit to the data 
 
 
 
3.2 Temporal Washout Study 
 
The feasibility of using the T1-mapping technique was also applied to study the 
manganese washout phenomena temporally. This is important because it will provide us 
with a quantitative means of measuring the rate of manganese efflux from the 
myocardium, and could also potentially provide information into individual compartment 
efflux rates. The temporal characteristics of ∆R1 post-MnCl2 infusion were studied in 
control mice infused at a single dose of 282.57±5.96 nmoles/g BW MnCl2. The washout 
period was examined from 0.2 – 99.2 hrs. Values of ∆R1 were calculated by subtracting 
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Figure 4 - Temporal Mn2+ washout curve. The x-axis shows experimental time course 
post-MnCl2 infusion, in hours. The y-axis shows the difference in relaxation rate, ∆R1, 
pre- vs. post-MnCl2 infusion. The insert plot shows the complete washout curve over an 
extended period of time 
 
 
 
the average baseline ROI R1 (  /sec,0.040.78  R LVWallbaseline,1, ±= from 33 control mice) from 
the post-MnCl2 infusion ROI R1 value. Figure 4 shows the temporal relationship of the 
Mn2+ washout curve in the LV Wall, while Table 2 summarizes the washout data for the 
LV Wall. The LV Wall ∆R1 signal has attenuated 50% in the first 2.5 hours post-infusion. 
Despite this initially rapid attenuation of the ∆R1 signal, there is a non-zero ∆R1 
value remaining until a few days post-infusion suggesting retention of the remaining 
Mn2+. During the first 9 hours post-infusion the washout data for this infusion dose can 
be fit exponentially with LV Wall -0.40·t1  /sec)e(5.24  R =Δ  (r2 = 0.93, with t given in units 
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Table 2 - Temporal ∆R1 signal attenuation post-MnCl2 infusion in the LV Wall. 
 
Time Post-MnCl2 Infusion (hrs) LV Wall ∆R1 (1/sec) 
0.31±0.11 (n=7) 4.44±1.48 
1.35±0.30 (n=3) 3.65±1.08 
2.41±0.37 (n=5) 2.23±0.75 
3.33±0.04 (n=2) 1.04±0.29 
4.25±0.41 (n=3) 0.70±0.16 
6.33±0.08 (n=2) 0.63±0.36 
7.34±0.37 (n=5) 0.45±0.35 
9.22±1.11 (n=2) 0.59±0.39 
11.40±0.54 (n=5) 0.64±0.16 
13.19±0.62 (n=2) 0.36±0.03 
21.11 (n=1) 0.14 
46.07±3.30 (n=3) 0.07±0.04 
99.19 (n=1) 0.08 
 
Values are expressed as mean ± SD, with sample size in parentheses 
 
 
 
of hours). At longer times further data is required to produce an exponential fit to assess 
potential compartmentalization. This information provides a better imaging timeframe for 
the cardiovascular disease model in the current study, with eventual information on 
potential extrudability of Mn2+ from the myocardium.  
 
3.3 Myocardial Infarction Study 
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The final part of this study involved utilizing the T1-mapping method under 
cardiovascular disease conditions to examine the feasibility of applying such a technique. 
In vivo concentration map calculations were performed on a mouse myocardial infarction 
model to investigate the ability of quantitatively assessing dynamic changes in 
manganese uptake in various regions of myocardial injury. All three groups of mice, 
namely control, sham-operated and myocardial infarction, were infused with a single 
dose of 282.50±4.00 nmoles/g BW MnCl2. The mice were imaged at 0.25±0.05 hrs after 
the initial MnCl2 infusion, as indicated from the temporal washout study to avoid 
modulated Mn2+ retention. Figure 5 shows sample post-MnCl2 infusion T1 maps for (a) 
sham-operated and (b) myocardial infarction mice. The sham-operated mouse shows a 
well defined LV Wall and interventricular septum with relatively uniform manganese 
uptake throughout. In the MI model there is substantial LV Wall thinning at the injury 
site, accompanied by higher T1 values due to reduced uptake of Mn2+. 
The results of this study are shown in Figure 6, where the data is presented as the 
average ROI ∆R1 (solid horizontal line) ± SD (shaded box), with the data range (solid 
vertical line). Table 3 also shows these results, along with the statistical test results. The 
relatively large sample size for the sham-operated group resulted from the time required 
to optimize the surgical technique, in preparation for consistent MI production. Twenty-
one sham-operated surgeries were performed to ensure consistency in the technique 
before performing MI surgery. Imaging results for all of the sham operations were self-
consistent (i.e., there is no image-based trend between the time of surgery and the value 
of LV Wall ∆R1). 
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Figure 5 - Example short-axis post-MnCl2 infusion T1 map cardiac images for; (a) a 
sham-operated mouse, and (b) a myocardial infarction mouse. Significant LV Wall 
thinning can be seen for the MI mouse with longer T1 relaxation times relative to healthy 
myocardial tissue. (b) shows the interventricular septum (S), myocardial infarction 
adjacent zone (Adjacent Zone) and myocardial infarction injury site (MI) 
 
 
 
There is no statistically significant difference between the LV Wall ∆R1 values of 
the control (4.49±1.63 /sec) and sham-operated (4.62±2.34 /sec) mice (p = 0.91) 
suggesting that the procedure of opening the chest does not affect Mn2+ uptake within the 
heart. Comparing the control and sham-operated LV Wall ∆R1 values with the MI 
adjacent zone ∆R1 values using ANOVA, however, shows that there is a significant 
difference in relaxivity between the groups (p = 0.03). Cross-comparison of all of the 
groups individually with t-tests demonstrates that the MI adjacent zone ∆R1 (2.00±0.49 
/sec) is significantly less than the control and sham-operated groups (p < 0.05), with the 
MI injury site ∆R1 (0.97±0.39 /sec) being significantly less (p < 0.05) than all of the 
groups. These results demonstrate the sensitivity of this technique to determine altered 
manganese uptake, not only at the necrotic site but also within the adjacent zone. 
Calculating the in vivo Mn concentration map could allow for potentially salvageable 
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myocardium to be identified for future therapeutic treatment or prevention, in preclinical 
models. 
 
 
 
 
Figure 6 - The effect of myocardial injury on the uptake of Mn2+. Regions of interest 
were defined for the LV Wall in the control and sham-operated groups. ROIs for the MI 
model were also defined at the injury site contained within the LV Wall and in the 
myocardial infarction adjacent zone, immediately surrounding the injury site. Data is 
presented as the average ROI ∆R1 (solid horizontal line, /sec) ± SD (shaded box), with 
the data range shown (solid vertical line). 
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Table 3 - Average ∆R1 signal enhancement post-MnCl2 infusion for control, sham-
operated and myocardial infarction groups. For the myocardial infarction group ROIs 
were defined both for the myocardial infarction adjacent zone, surrounding the infarction 
site, and the infarcted site (MI). 
 
Group - Region of Interest (ROI) ROI ∆R1 (1/sec) 
Control – LV Wall 4.49±1.63 (n=6)†*‡ 
Sham-Operated – LV Wall 4.62±2.34 (n=21) 
Myocardial Infarction – Adjacent Zone 2.00±0.49 (n=6) 
Myocardial Infarction – MI Site 0.97±0.39 (n=6) 
 
Values are expressed as mean ± SD, with sample size in parentheses 
†p = 0.03 between all LV Wall groups (ANOVA, single factor) 
*p = 0.91 between control and sham-operated LV Wall groups (unpaired two-tailed t-test) 
‡p < 0.05 between every two group combination except the control and sham-operated 
LV Wall combination (unpaired two-tailed t-test) 
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CHAPTER 4 
DISCUSSION 
 
 
 
It has previously been shown (51) that T1-weighted MEMRI in a murine MI 
model provides clear delineation of the myocardial infarction site. The present study has 
demonstrated the quantitative ability of MEMRI T1-mapping in the murine heart to 
determine cellular viability in the vicinity of the myocardial infarction site. This could 
ultimately lead to an early in vivo indicator of viable treatment options depending on the 
state of the myocytes and their potential salvageability. 
T1-mapping of cardiac MEMRI has demonstrated enough sensitivity to provide 
quantitative information over the range of MnCl2 doses used in our experiment. By 
demonstrating the dynamic range of relaxivity changes over a range of MnCl2 infusion 
doses this method can provide a means of optimizing MnCl2 infusion protocols. Mn2+ is 
know to be cardiotoxic at high doses (55). However, we have demonstrated a large range 
of signal enhancement at subtoxic levels. Due to this fact, lower doses of MnCl2 can be 
used while still producing significant relaxivity changes.  
Results of the dose dependent study (Figure 2) not only allow for the design of 
contrast agent optimal doses to minimize toxicity concerns, but also allow in vivo 
estimates of absolute Mn concentration following LV Wall ∆R1 calculations. This 
technique can therefore be used to monitor the in vivo Mn levels non-invasively. One 
interesting observation is the non-linear relationship between the total MnCl2 infusion 
dose and the LV Wall ∆R1. Instead of a purely linear increase in signal intensity 
enhancement a plateau region occurs at a dose above 197 nmoles/g BW, likely due to 
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physiological effects. This is in good agreement with previously reported results (23). 
Following the same non-linear form as the total infusion dose, it is seen that above 
approximately 100 μg/g dry heart weight, the absolute Mn concentration also reaches a 
plateau. Within this plateau there is no increase in ∆R1 following an increase in absolute 
heart manganese concentration. As the infusion of MnCl2 increases, the absolute Mn 
content of the heart also increases (Figure 3a), but ∆R1 reaches a plateau at 4.61 /sec. 
The plateau effect can be potentially explained in a number of ways, either due to 
the limitations of Ca2+ uptake, or due to limited compartmentalization. The cellular 
binding sites could become saturated at a certain dose, limiting the uptake of Mn2+. 
Another explanation for the plateau phenomena could be due to a gradient effect whereby 
the cells become saturated and are unable to uptake more Mn2+. Similarly, Mn2+ could 
have an inhibitory effect on the Ca2+ channels, limiting the scope for Mn2+ uptake. 
Further observations are necessary to decipher the physiology of this phenomenon. 
The non-zero intercept in Figure 2 is in part due to the finite length of infusion 
tubing attached to the tail vein needle. A short, 9.9±0.4 cm, length of PE10 tubing 
containing saline solution connects the infusion needle to the MnCl2 infusion line. This 
length of tubing corresponds to an equivalent infusion dose of 16.3±0.7 nmoles/g BW 
MnCl2. This helps to validate our assumption for the low dose linear fit, where at doses 
below 16.3 nmoles/g BW there is assumed to be no manganese infusion and 0  R1 =Δ . 
Despite the number of applications of Mn2+ as an MRI contrast agent, little detail 
is known about the efflux mechanisms of Mn2+ from myocytes. The signal washout from 
the LV Wall is shown in Figure 4. After 2.5 hours 50% of the ∆R1 signal had been 
attenuated in the LV Wall, with a small non-zero ∆R1 remaining until a few days post-
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infusion. In comparison, it has been shown in a rat model that manganese is cleared from 
all the major organs within 24 hours (69). 
The form of this washout curve is still uncertain; numerical modeling of Mn 
transport may provide additional insight. The complicated form of this curve could 
contain information about the Mn2+ efflux mechanisms within the myocardium. 
Accumulation of Mn2+ in various compartments within the myocytes could explain the 
variations between the initially rapid washout and the sustained signal enhancement over 
a few days. Differences in individual compartment efflux rates would contribute to the 
washout curve. One potential efflux mechanism is via the sodium-calcium exchanger 
(NCX). The NCX is an important transporter for the regulation of intracellular Ca2+ 
concentration (70). By altering the characteristics of different efflux mechanisms, such as 
the NCX channel, it might be possible to further interrogate the form of the curve and the 
underlying physiology. This information, along with the use of physiological modulators 
such as pharmaceutical agents, could be critical for examining potential Mn2+ 
extrudability pathways. This technique could also provide a means of identifying Mn2+ 
efflux modulation due to myocardial injury. 
The myocardial infarction study utilized the optimal dose and timing properties 
acquired from the previous sections of this study. We are able to show statistically 
significant differences between healthy myocardial tissue, in the control and sham-
operated groups, and the MI adjacent zone in the MI group. Mn2+ had previously been 
shown to provide functional, pathological and viability data in myocardial tissue using 
T1-weighted imaging techniques in mice (51) and dogs (52). Manganese-dipyridoxyl 
diphosphate (MnDPDP), a Mn2+ releasing contrast agent (71), is currently approved for 
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clinical liver imaging. MnDPDP-enhanced images have demonstrated manganese 
retention in viable pig myocardium (72) with clearance of manganese from infarcted 
myocytes in a rat model (50). This behavior is consistent with MEMRI contrast. 
Recently, MnDPDP has been used as a viability marker in patients with myocardial 
infarction (47). However, more quantitative information was required to be able to assess 
the extent of damage to the myocardium, which we have demonstrated through the T1-
mapping protocol. 
Myocardial infarction causes physiological remodeling leading to potential Ca2+ 
handling alterations. This remodeling process can potentially be observed and monitored 
using manganese enhanced T1-mapping as shown by the sensitivity of our data. The 
injury site of the LV Wall showed a ∆R1 almost 5 times less than the healthy LV Wall of 
the control mouse. More interestingly, with respect to recovery of the injured tissue, this 
technique is sensitive to the reduced uptake of Mn2+ in the adjacent zone. During 
myocardial ischemia intracellular calcium concentrations increase due to increased Ca2+ 
influx and reduced efflux (9). However, our results show reduced Mn2+ uptake in both the 
MI site and adjacent zone. 
The phenomena of reduced Mn2+ uptake in both the MI region and the adjacent 
zone are complex to address. To date conflicting results have been reported in other 
studies. In vivo manganese enhanced MRI has observed signal attenuations in mice (51), 
rat (73) and larger mammalian species (74). However, in vitro studies have shown 
enhanced Ca2+ influx as a way of a compensatory process (75). 
Camellitti, et al. (76) have shown ex vivo results which demonstrate small islands 
of viable myocytes in ischemic regions. These islands could potentially explain the non-
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zero Mn2+ uptake in the ischemic regions. In the adjacent area we suggest that the volume 
of viable tissue is still reduced as compared to healthy LV Wall tissue of the control and 
sham operated mice. This could potentially explain the reduction of Mn2+ uptake in this 
area. Temporal responses to myocardial infarction could now be predicted in mice using 
this preclinical model, looking at the alterations in calcium handling with recovery. 
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CHAPTER 5 
CONCLUSIONS 
 
 
 
This study demonstrates that T1-mapping of cardiac manganese-enhanced MRI 
can be used to quantify in vivo Mn concentrations and define regions of potentially 
altered Ca2+ homeostasis in a myocardial infarction model. The effect of manganese 
infusion dose has been studied up to approximately 297 nmoles/g BW, with an initial 
slow uptake occurring below 61 nmoles/g BW, and a more rapid uptake until 197 
nmoles/g BW. At this dose the physiological steady state was achieved. 
Mn2+ washout has also been investigated in the LV Wall. The ∆R1 signal is 
attenuated to 50% of the steady state signal in approximately 2.5 hours post-infusion. 
There is still a ∆R1 effect remaining after a few days suggesting potential Mn2+ retention 
at the site. The overall washout progression warrants further investigation, but this 
technique could provide a potential way to examine the extrudability of Mn2+ from the 
myocardium. 
One motivation for this study is that myocardial infarction causes physiological 
remodeling leading to potential Ca2+ handling alteration. With the potential of using T1-
mapping and ICP-MS analysis to quantify the in vivo concentration of Mn, more insight 
into myocardial infarction adjacent zones may be provided. This technique could provide 
additional information such as: (1) optimization of the MnCl2 dose to minimize the study 
dose; (2) quantification of Mn concentration in vivo; (3) temporal response of myocardial 
infarction or ischemic-reperfusion model(s); (4) pharmacological efficacy; and (5) 
potential preclinical and translational models to monitor disease treatment. 
36 
REFERENCES 
 
 
 
 
1. Dhalla NS, Pierce GN, Panagia V, Singal PK, Beamish RE. Calcium movements 
in relation to heart function. Basic research in cardiology 1982; 77; 2: 117-139. 
2. Wier WG. Intracellular calcium during excitation-contraction coupling in 
mammalian ventricle. Medicine and science in sports and exercise 1991; 23; 10: 
1149-1156. 
3. Mukherjee R, Spinale FG. L-type calcium channel abundance and function with 
cardiac hypertrophy and failure: a review. Journal of molecular and cellular 
cardiology 1998; 30; 10: 1899-1916. 
4. Eisner DA, Sipido KR. Sodium calcium exchange in the heart: necessity or 
luxury? Circulation research 2004; 95; 6: 549-551. 
5. Caroni P, Carafoli E. An ATP-dependent Ca2+-pumping system in dog heart 
sarcolemma. Nature 1980; 283; 5749: 765-767. 
6. Houser SR, Piacentino V, 3rd, Weisser J. Abnormalities of calcium cycling in the 
hypertrophied and failing heart. Journal of molecular and cellular cardiology 
2000; 32; 9: 1595-1607. 
7. Saini HK, Shao Q, Musat S, Takeda N, Tappia PS, Dhalla NS. Imidapril 
treatment improves the attenuated inotropic and intracellular calcium responses to 
ATP in heart failure due to myocardial infarction. British journal of 
pharmacology 2005; 144; 2: 202-211. 
8. Zhang XQ, Musch TI, Zelis R, Cheung JY. Effects of impaired Ca2+ homeostasis 
on contraction in postinfarction myocytes. J Appl Physiol 1999; 86; 3: 943-950. 
9. Menown IB, Adgey AA. Cardioprotective therapy and sodium-hydrogen 
exchange inhibition: current concepts and future goals. Journal of the American 
College of Cardiology 2001; 38; 6: 1651-1653. 
10. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-
apoptosis link. Nature reviews 2003; 4; 7: 552-565. 
37 
11. Sam F, Sawyer DB, Chang DL, Eberli FR, Ngoy S, Jain M, Amin J, Apstein CS, 
Colucci WS. Progressive left ventricular remodeling and apoptosis late after 
myocardial infarction in mouse heart. American journal of physiology 2000; 279; 
1: H422-428. 
12. Lerman A, Zeiher AM. Endothelial function: cardiac events. Circulation 2005; 
111; 3: 363-368. 
13. Jain AP, Mohan A, Gupta OP, Jajoo UN, Kalantri SP, Srivastava LM. Role of 
oxygen free radicals in causing endothelial damage in acute myocardial 
infarction. The Journal of the Association of Physicians of India 2000; 48; 5: 478-
480. 
14. van Dokkum RP, Eijkelkamp WB, Kluppel AC, Henning RH, van Goor H, Citgez 
M, Windt WA, van Veldhuisen DJ, de Graeff PA, de Zeeuw D. Myocardial 
infarction enhances progressive renal damage in an experimental model for 
cardio-renal interaction. J Am Soc Nephrol 2004; 15; 12: 3103-3110. 
15. Roy D, Quiles J, Sinha M, Aldama G, Gaze D, Kaski JC. Effect of direct-current 
cardioversion on ischemia-modified albumin levels in patients with atrial 
fibrillation. The American journal of cardiology 2004; 93; 3: 366-368. 
16. Tsutsui H, Ide T, Hayashidani S, Suematsu N, Shiomi T, Wen J, Nakamura K, 
Ichikawa K, Utsumi H, Takeshita A. Enhanced generation of reactive oxygen 
species in the limb skeletal muscles from a murine infarct model of heart failure. 
Circulation 2001; 104; 2: 134-136. 
17. Lindley TE, Doobay MF, Sharma RV, Davisson RL. Superoxide is involved in 
the central nervous system activation and sympathoexcitation of myocardial 
infarction-induced heart failure. Circulation research 2004; 94; 3: 402-409. 
18. Mendonca-Dias MH, Gaggelli E, Lauterbur PC. Paramagnetic contrast agents in 
nuclear magnetic resonance medical imaging. Seminars in nuclear medicine 1983; 
13; 4: 364-376. 
19. Cory DA, Schwartzentruber DJ, Mock BH. Ingested manganese chloride as a 
contrast agent for magnetic resonance imaging. Magnetic resonance imaging 
1987; 5; 1: 65-70. 
38 
20. Anderson M. Mn ions pass through calcium channels. A possible explanation. The 
Journal of general physiology 1983; 81; 6: 805-827. 
21. Narita K, Kawasaki F, Kita H. Mn and Mg influxes through Ca channels of motor 
nerve terminals are prevented by verapamil in frogs. Brain research 1990; 510; 2: 
289-295. 
22. Shibuya I, Douglas WW. Indications from Mn-quenching of Fura-2 fluorescence 
in melanotrophs that dopamine and baclofen close Ca channels that are 
spontaneously open but not those opened by high [K+]O; and that Cd 
preferentially blocks the latter. Cell calcium 1993; 14; 1: 33-44. 
23. Hu TC, Pautler RG, MacGowan GA, Koretsky AP. Manganese-enhanced MRI of 
mouse heart during changes in inotropy. Magn Reson Med 2001; 46; 5: 884-890. 
24. Skjold A, Kristoffersen A, Vangberg TR, Haraldseth O, Jynge P, Larsson HB. An 
apparent unidirectional influx constant for manganese as a measure of myocardial 
calcium channel activity. J Magn Reson Imaging 2006; 24; 5: 1047-1055. 
25. Bloembergen N, Morgan LO. Proton Relaxation Times in Paramagnetic 
Solutions: Effects of Electron Spin Relaxation. J Chem Phys 1961; 34: 842-850. 
26. Roose P, Van Craen J, Andriessens G, Eisendrath H. NMR Study of Spin–Lattice 
Relaxation of Water Protons by Mn2+Adsorbed onto Colloidal Silica. Journal of 
Magnetic Resonance, Series A 1996; 120; 2: 206-213. 
27. Stephens EM, Grisham CM. Lithium-8 Nuclear Magnetic Resonance, water 
proton nuclear magnetic resonance, and gadolinium electron paramagnetic 
resonance studies of the sarcoplasmic reticulum calcium ion transport adenosine 
triphosphatase. Biochemistry 1979; 18: 4876-4885. 
28. Tofts P. Quantitative MRI of the Brain: Measuring Changes by Disease: Wiley; 
2003. 
29. Lauterbur PC. Image Formation by Induced Local Interactions: Examples 
Employing Nuclear Magnetic Resonance. Nature 1973; 242: 190-191. 
30. Bers DM. Calcium fluxes involved in control of cardiac myocyte contraction. 
Circulation research 2000; 87; 4: 275-281. 
39 
31. Pogwizd SM, Schlotthauer K, Li L, Yuan W, Bers DM. Arrhythmogenesis and 
contractile dysfunction in heart failure: Roles of sodium-calcium exchange, 
inward rectifier potassium current, and residual beta-adrenergic responsiveness. 
Circulation research 2001; 88; 11: 1159-1167. 
32. Saeed M. New concepts in characterization of ischemically injured myocardium 
by MRI. Experimental biology and medicine (Maywood, NJ 2001; 226; 5: 367-
376. 
33. Taylor AM, Panting JR, Keegan J, Gatehouse PD, Amin D, Jhooti P, Yang GZ, 
McGill S, Burman ED, Francis JM, Firmin DN, Pennell DJ. Safety and 
preliminary findings with the intravascular contrast agent NC100150 injection for 
MR coronary angiography. J Magn Reson Imaging 1999; 9; 2: 220-227. 
34. Szolar DH, Saeed M, Wendland MF, Sakuma H, Roberts TP, Stiskal MA, 
Derugin N, Higgins CB. MR imaging characterization of postischemic 
myocardial dysfunction ("stunned myocardium"): relationship between functional 
and perfusion abnormalities. J Magn Reson Imaging 1996; 6; 4: 615-624. 
35. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, Bundy J, Finn 
JP, Klocke FJ, Judd RM. Relationship of MRI delayed contrast enhancement to 
irreversible injury, infarct age, and contractile function. Circulation 1999; 100; 
19: 1992-2002. 
36. Yu X, Zou J, Babb JS, Johnson G, Sanes DH, Turnbull DH. Statistical mapping of 
sound-evoked activity in the mouse auditory midbrain using Mn-enhanced MRI. 
NeuroImage 2008; 39; 1: 223-230. 
37. van der Zijden JP, Wu O, van der Toorn A, Roeling TP, Bleys RL, Dijkhuizen 
RM. Changes in neuronal connectivity after stroke in rats as studied by serial 
manganese-enhanced MRI. NeuroImage 2007; 34; 4: 1650-1657. 
38. Pautler RG, Silva AC, Koretsky AP. In vivo neuronal tract tracing using 
manganese-enhanced magnetic resonance imaging. Magn Reson Med 1998; 40; 5: 
740-748. 
39. Weng JC, Chen JH, Yang PF, Tseng WY. Functional mapping of rat barrel 
activation following whisker stimulation using activity-induced manganese-
dependent contrast. NeuroImage 2007; 36; 4: 1179-1188. 
40 
40. Lin YJ, Koretsky AP. Manganese ion enhances T1-weighted MRI during brain 
activation: an approach to direct imaging of brain function. Magn Reson Med 
1997; 38; 3: 378-388. 
41. Van Meir V, Pavlova D, Verhoye M, Pinxten R, Balthazart J, Eens M, Van der 
Linden A. In vivo MR imaging of the seasonal volumetric and functional 
plasticity of song control nuclei in relation to song output in a female songbird. 
NeuroImage 2006; 31; 3: 981-992. 
42. Chen W, Tenney J, Kulkarni P, King JA. Imaging unconditioned fear response 
with manganese-enhanced MRI (MEMRI). NeuroImage 2007; 37; 1: 221-229. 
43. Minoshima S, Cross D. In vivo imaging of axonal transport using MRI: aging and 
Alzheimer's disease. European journal of nuclear medicine and molecular 
imaging 2008; 35 Suppl 1: S89-92. 
44. Smith KD, Kallhoff V, Zheng H, Pautler RG. In vivo axonal transport rates 
decrease in a mouse model of Alzheimer's disease. NeuroImage 2007; 35; 4: 
1401-1408. 
45. Aoki I, Takahashi Y, Chuang KH, Silva AC, Igarashi T, Tanaka C, Childs RW, 
Koretsky AP. Cell labeling for magnetic resonance imaging with the T1 agent 
manganese chloride. NMR in biomedicine 2006; 19; 1: 50-59. 
46. Gimi B, Leoni L, Oberholzer J, Braun M, Avila J, Wang Y, Desai T, Philipson 
LH, Magin RL, Roman BB. Functional MR microimaging of pancreatic beta-cell 
activation. Cell transplantation 2006; 15; 2: 195-203. 
47. Skjold A, Amundsen BH, Wiseth R, Stoylen A, Haraldseth O, Larsson HB, Jynge 
P. Manganese dipyridoxyl-diphosphate (MnDPDP) as a viability marker in 
patients with myocardial infarction. J Magn Reson Imaging 2007; 26; 3: 720-727. 
48. Saeed M, Higgins CB, Geschwind JF, Wendland MF. T1-relaxation kinetics of 
extracellular, intracellular and intravascular MR contrast agents in normal and 
acutely reperfused infarcted myocardium using echo-planar MR imaging. 
European radiology 2000; 10; 2: 310-318. 
49. Wendland MF, Saeed M, Lund G, Higgins CB. Contrast-enhanced MRI for 
quantification of myocardial viability. J Magn Reson Imaging 1999; 10; 5: 694-
702. 
41 
50. Bremerich J, Saeed M, Arheden H, Higgins CB, Wendland MF. Normal and 
infarcted myocardium: differentiation with cellular uptake of manganese at MR 
imaging in a rat model. Radiology 2000; 216; 2: 524-530. 
51. Hu TC, Bao W, Lenhard SC, Schaeffer TR, Yue TL, Willette RN, Jucker BM. 
Simultaneous assessment of left-ventricular infarction size, function and tissue 
viability in a murine model of myocardial infarction by cardiac manganese-
enhanced magnetic resonance imaging (MEMRI). NMR in biomedicine 2004; 17; 
8: 620-626. 
52. Hu TC, Christian TF, Aletras AH, Taylor JL, Koretsky AP, Arai AE. Manganese 
enhanced magnetic resonance imaging of normal and ischemic canine heart. 
Magn Reson Med 2005; 54; 1: 196-200. 
53. Skjold A, Vangberg TR, Kristoffersen A, Haraldseth O, Jynge P, Larsson HB. 
Relaxation enhancing properties of MnDPDP in human myocardium. J Magn 
Reson Imaging 2004; 20; 6: 948-952. 
54. Greger JL. Dietary standards for manganese: overlap between nutritional and 
toxicological studies. The Journal of nutrition 1998; 128; 2 Suppl: 368S-371S. 
55. Brurok H, Schjott J, Berg K, Karlsson JO, Jynge P. Effects of manganese 
dipyridoxyl diphosphate, dipyridoxyl diphosphate--, and manganese chloride on 
cardiac function. An experimental study in the Langendorff perfused rat heart. 
Investigative radiology 1995; 30; 3: 159-167. 
56. Damadian R. Tumor detection by nuclear magnetic resonance. Science (New 
York, NY 1971; 171; 976: 1151-1153. 
57. Mansfield P, Maudsley AA. Line scan proton spin imaging in biological 
structures by NMR. Physics in medicine and biology 1976; 21; 5: 847-852. 
58. Mansfield P, Morris PG, Ordidge RJ, Pykett IL, Bangert V, Coupland RE. Human 
whole body imaging and detection of breast tumours by n.m.r. Phil Trans R Soc 
Lond B 1980; 289: 503-510. 
59. Chuang KH, Koretsky A. Improved neuronal tract tracing using manganese 
enhanced magnetic resonance imaging with fast T1 mapping. Magn Reson Med 
2006; 55; 3: 604-611. 
42 
60. Shah NJ, Neeb H, Zaitsev M, Steinhoff S, Kircheis G, Amunts K, Haussinger D, 
Zilles K. Quantitative T1 mapping of hepatic encephalopathy using magnetic 
resonance imaging. Hepatology (Baltimore, Md 2003; 38; 5: 1219-1226. 
61. Lee JH, Silva AC, Merkle H, Koretsky AP. Manganese-enhanced magnetic 
resonance imaging of mouse brain after systemic administration of MnCl2: dose-
dependent and temporal evolution of T1 contrast. Magn Reson Med 2005; 53; 3: 
640-648. 
62. Look DC, Locker DR. Nuclear Spin-Lattice Relaxation Measurements by Tone-
Burst Modulation. Physical Review Letters 1968; 20; 18: 987-989. 
63. Look DC, Locker DR. Time Saving in Measurement of NMR and EPR 
Relaxation Times. The Review of Scientific Instruments 1970; 41; 2: 250-251. 
64. Crawley AP, Henkelman RM. A comparison of one-shot and recovery methods in 
T1 imaging. Magn Reson Med 1988; 7; 1: 23-34. 
65. Brix G, Schad LR, Deimling M, Lorenz WJ. Fast and precise T1 imaging using a 
TOMROP sequence. Magnetic resonance imaging 1990; 8; 4: 351-356. 
66. Steinhoff S, Zaitsev M, Zilles K, Shah NJ. Fast T1 mapping with volume 
coverage. Magn Reson Med 2001; 46; 1: 131-140. 
67. Frahm J, Haase A, Matthaei D. Rapid NMR imaging of dynamic processes using 
the FLASH technique. Magn Reson Med 1986; 3; 2: 321-327. 
68. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality 
medical image analysis. Mol Imaging 2003; 2; 3: 131-137. 
69. Ni Y, Petre C, Bosmans H, Miao Y, Grant D, Baert AL, Marchal G. Comparison 
of manganese biodistribution and MR contrast enhancement in rats after 
intravenous injection of MnDPDP and MnCl2. Acta Radiol 1997; 38; 4 Pt 2: 700-
707. 
70. Shigekawa M, Iwamoto T. Cardiac Na+-Ca2+ exchange: molecular and 
pharmacological aspects. Circulation research 2001; 88; 9: 864-876. 
43 
71. Federle MP, Chezmar JL, Rubin DL, Weinreb JC, Freeny PC, Semelka RC, 
Brown JJ, Borello JA, Lee JK, Mattrey R, Dachman AH, Saini S, Harmon B, 
Fenstermacher M, Pelsang RE, Harms SE, Mitchell DG, Halford HH, Anderson 
MW, Johnson CD, Francis IR, Bova JG, Kenney PJ, Klippenstein DL, Foster GS, 
Turner DA. Safety and efficacy of mangafodipir trisodium (MnDPDP) injection 
for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials 
(safety). J Magn Reson Imaging 2000; 12; 1: 186-197. 
72. Eriksson R, Johansson L, Bjerner T, Briley Saebo K, Ahlstrom H. Uptake of 
MnCl2 and mangafodipir trisodium in the myocardium: a magnetic resonance 
imaging study in pigs. J Magn Reson Imaging 2004; 19; 5: 564-569. 
73. Krombach GA, Saeed M, Higgins CB, Novikov V, Wendland MF. Contrast-
enhanced MR delineation of stunned myocardium with administration of MnCl2 
in rats. Radiology 2004; 230; 1: 183-190. 
74. Storey P, Chen Q, Li W, Seoane PR, Harnish PP, Fogelson L, Harris KR, Prasad 
PV. Magnetic resonance imaging of myocardial infarction using a manganese-
based contrast agent (EVP 1001-1): preliminary results in a dog model. J Magn 
Reson Imaging 2006; 23; 2: 228-234. 
75. Corretti MC, Koretsune Y, Kusuoka H, Chacko VP, Zweier JL, Marban E. 
Glycolytic inhibition and calcium overload as consequences of exogenously 
generated free radicals in rabbit hearts. The Journal of clinical investigation 1991; 
88; 3: 1014-1025. 
76. Camelliti P, Devlin GP, Matthews KG, Kohl P, Green CR. Spatially and 
temporally distinct expression of fibroblast connexins after sheep ventricular 
infarction. Cardiovascular research 2004; 62; 2: 415-425. 
 
 
